DETAILED NOTES ON TRASTUZUMAB CHEMOTHERAPY

One of the most under-investigated “driving forces” associated with trastuzumab resistance is PTEN. Nagata et al. (2004) reported which the loss of PTEN was observed in 36% of HER2-positive Major breast tumor specimens from people with stage IV illness. On top of that, they also showed that patients with PTEN-deficient tumors had remarkably low